Status:

RECRUITING

Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and Non-Traumatic Spinal Cord Injury: A Pilot Study

Lead Sponsor:

Francis Farhadi

Conditions:

Spinal Cord Stimulation

Electric Stimulation Therapy

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The study will be a non-randomized, non-blinded pilot study to analyze the safety and feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The aim is to include 30 tot...

Detailed Description

Spinal cord injury (SCI) can result from primary physical insults such as acute trauma, or secondary insults that result from chronic compression and ischemia. The resultant neurological impairment le...

Eligibility Criteria

Inclusion

  • Age: = 18 years and = 80 years.
  • Written informed consent by patient and/or legal authorized representative (LAR).
  • No other life-threatening condition.
  • No evidence of sepsis.
  • No evidence of superficial skin infection at site of surgery and intervention.
  • An established diagnosis of either:
  • cervical myelopathy with modified Japanese Orthopaedic Association score of 8-14, or
  • acute cervical / thoracic SCI with ASIA Impairment Scale grade A-D (as assessed within 72 hours of injury) with neurologic level of injury (NLI) from C2 to T12.
  • The ability to undergo, or have had, surgical intervention. -. The ability to undergo transcutaneous intervention including study procedures in the posterior cervical or thoracic midline at or after 14 days from surgery.

Exclusion

  • Any concomitant impairment of the upper and lower limb at baseline that could potentially confound the neurologic assessments; including but not limited to traumatic or disease conditions like brachial plexus injury, peripheral neuropathy, spinal hematoma, transverse myelitis, non-compressive myelopathy, dementia, and Parkinson's disease.
  • mJOA of \>= 15 and \<= 7, or AIS grade E tSCI at baseline assessment.
  • Currently involved in another non-observational ntSCI or tSCI study, or receiving another interventional drug, that could interfere with recordings and confound adverse events.
  • Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation, at discretion of the treating surgeon and/or principal investigator.
  • Unable to commit to the follow-up schedule.
  • Recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study.
  • Any condition likely to result in the patient's death within the next 12 months.
  • Prisoner.
  • Pregnancy.
  • Cardiac pacemaker dependent, unable to undergo electrical stimulation.
  • Brain implant, skull prosthesis, plate and screws limiting transcranial stimulation.
  • Tattoo at site of skin electrode that causes heat/pain during stimulation.
  • Subjects who in the opinion of the investigator are not suitable for inclusion in the study, with reason documented.

Key Trial Info

Start Date :

October 23 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2026

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06520020

Start Date

October 23 2024

End Date

June 30 2026

Last Update

June 6 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Kentucky - Chandler Medical Center

Lexington, Kentucky, United States, 40536-0298